Relationship between osteoprotegerin and mortality in decompensated heart failure with preserved ejection fraction.

AIM: The aim of this study was to evaluate whether osteoprotegerin - an emerging inflammatory biomarker in cardiovascular diseases - predicts outcomes in patients with acute heart failure and preserved ejection fraction. METHODS: We measured urea, creatinine, hemoglobin, high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide and osteoprotegerin on admission in 177 patients admitted with decompensated heart failure and left ventricular ejection fraction at least 45%. The population was divided according to the median values of osteoprotegerin (158.6 ng/l). Primary and secondary endpoints were all-cause mortality and death/readmission at 1-year follow-up, respectively. Multivariable Cox models were generated for osteoprotegerin and common risk factors. We also evaluated the reclassification of patients into risk categories after adding this biomarker to the model. RESULTS: A total of 43 patients died during the follow-up and 84 had a combined event. Kaplan-Meier curves showed significantly increased primary and secondary endpoints according to the median of osteoprotegerin (log-rank, P < 0.0001 and 0.001, respectively). After adjustment for age, estimated glomerular filtration rate, hemoglobin, N-terminal pro-B-type natriuretic peptide, BMI and New York Heart Association III-IV, osteoprotegerin was a significant predictor of primary endpoint evaluated as continuous and categorized variable (relative risk 2.49, 95% confidence interval 1.18-5.24, P = 0.016 and relative risk 2.35, 95% confidence interval 1.11-4.96, P = 0.025, respectively). The clinical prediction model with osteoprotegerin evaluated with Net Reclassification Index was not significant. CONCLUSION: Osteoprotegerin is independently associated with all-cause mortality in patients hospitalized for heart failure with preserved ejection fraction. However, adding this biomarker into a risk model does not improve its prediction value.

Troponin T in acute heart failure: clinical implications and prognosis in the Spanish National Registry on Heart Failure.

BACKGROUND: Elevated troponin in heart failure has been associated with worse prognosis, but there are differences in the design and results of published studies. Our objective was to determine the association of troponin T with mortality and readmissions in patients with acute heart failure in clinical practice conditions. METHODS: We included patients from the RICA registry who were hospitalized for acute heart failure. They were classified into 3 groups according to troponin T levels: normal, intermediate and high (<0.02, 0.02-0.049 and ≥ 0.05 ng/mL, respectively). Survival was studied by Kaplan-Meier curves and the association of variables was tested by Cox regression analysis. RESULTS: A total of 406 patients was included. Average age was 76.9 (76.0-77.7) years. Hypertensive heart disease was the most common etiology. Left ventricular ejection fraction was <45% in 22.1% of the patients. The group with elevated troponin T had higher proportions of women, systolic dysfunction, renal failure and anemia, a lower body mass index and longer hospital stay. At one year, patients with elevated troponin T had higher mortality than patients with normal troponin (35.5 vs. 13.9%, p<0.001). The composite event (mortality and readmissions) was also more frequent (51.6 vs. 30.9%, p<0.001), but there were no differences in readmissions alone. Troponin T ≥ 0.02 ng/mL was independently associated with mortality. CONCLUSIONS: Elevated troponin T levels are common in patients with heart failure in clinical practice and are associated with increased mortality and events after one year of follow-up.

Etiología y tratamiento de la anemia en la insuficiencia cardíaca. Estudio GESAIC / Etiology and clinical management of anemia in heart failure. GESAIC study

Fundamento y objetivo: Los trabajos sobre anemia en la insuficiencia cardíaca (IC) tienden a aceptar la anemia como una disfunción cardiorrenal combinada, sin realizar estudios etiológicos, omitiendo su carácter sindrómico. Nuestro objetivo es conocer el perfil etiológico y el tratamiento de la anemia en la IC en el medio hospitalario. Pacientes y método: Análisis transversal inicial de una cohorte multicéntrica de pacientes con IC y anemia recogidos de forma prospectiva. Utilizamos los criterios de la Organización Mundial de la Salud (OMS) para definir anemia, la ecuación Modification of Diet in Renal Disease (MDRD) para el cálculo del filtrado glomerular y unos criterios comunes para definir la etiología de la anemia. Resultados: Se incluyó a 228 pacientes, con edad media de 79,1 años, y el 59,65% mujeres. El 36,8% tenía anemia ferropénica y el 30,3% anemia de enfermedad crónica. En el 12,7% de los casos no se llegó a ningún diagnóstico etiológico. La variable con mayor potencia asociada a anemia ferropénica fue el tratamiento previo con antiagregantes (odds ratio [OR]=1,99; intervalo de confianza [IC] del 95%, 1,13¿3,53) y para anemia de enfermedad crónica, los bloqueadores del sistema renina angiotensina (SRA) (OR=3,29; IC del 95%, 1,36¿7,94). La anemia sin diagnóstico se asociaba con IC en su inicio (OR=5,41; IC del 95%, 1,65¿17,65). Recibió transfusión el 8,1% de los pacientes; un 6%, eritropoyetina, y el 25,3%, suplementos de hierro. La edad (OR=1,04; IC del 95%, 1¿1,08) y un valor más bajo de hemoglobina al ingreso (OR=1,81; IC del 95%, 1,46¿2,25) determinaron una actitud activa de tratamiento. Conclusiones: Un protocolo clínico de estudio de la anemia en la IC permite en un 70% de los casos un diagnóstico etiológico y un tratamiento más eficaz (AU)

Background and objective: Studies about anemia in heart failure (HF) tend to link the anemia to a cardio-renal dysfunction, and its syndromic value is seldom evaluated. Our objective was to assess the etiology and clinical management of anemia in HF patients in a hospital setting. Patients and method: Initial cross-sectional analysis of a multi-center and prospective cohort of patients with HF and anemia. Anemia was defined according to the WHO criteria; the Modification of Diet in Renal Disease equation was used to assess glomerular filtration and the etiology of anemia was defined according to common criteria. Results: We evaluated 228 patients, with a median age of 79.1 years and 59.65% women. Iron deficiency anemia was present in 36,8% of patients and anemia of chronic disease in 30.3%. Of note, 12.7% cases did not meet any etiological criteria. The main factor associated with iron deficiency was anti-platelet therapy (OR=1.99; 95% CI, 1.16¿1.68) and the main factors associated with anemia of chronic disease were the use of angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor antagonists (ARA-II) (OR=3.29; 95% CI, 1.36¿7.94). The main factor associated with undefined anemia was initial heart failure (OR=5.41; 95% CI, 1.65¿17.65). On the other hand, 8.1% of patients required transfusion, 6% were treated with erythropoietin and 25.3% were treated with iron. Both age (OR=1.04; 95% CI, 1¿1.08) and hemoglobin level at admission (OR=1.81; 95% CI, 1.46¿2.25) were associated with active treatment for anemia. Conclusions: A clinical study of anemia in patients with HF can establish an etiological diagnosis in 70% of cases, resulting in a more effective treatment (AU)

[Etiology and clinical management of anemia in heart failure. GESAIC Study]. / Etiología y tratamiento de la anemia en la insuficiencia cardíaca. Estudio GESAIC.

BACKGROUND AND OBJECTIVE: Studies about anemia in heart failure (HF) tend to link the anemia to a cardio-renal dysfunction, and its syndromic value is seldom evaluated. Our objective was to assess the etiology and clinical management of anemia in HF patients in a hospital setting. PATIENTS AND METHOD: Initial cross-sectional analysis of a multi-center and prospective cohort of patients with HF and anemia. Anemia was defined according to the WHO criteria; the Modification of Diet in Renal Disease equation was used to assess glomerular filtration and the etiology of anemia was defined according to common criteria. RESULTS: We evaluated 228 patients, with a median age of 79.1 years and 59.65% women. Iron deficiency anemia was present in 36,8% of patients and anemia of chronic disease in 30.3%. Of note, 12.7% cases did not meet any etiological criteria. The main factor associated with iron deficiency was anti-platelet therapy (OR=1.99; 95% CI, 1.16-1.68) and the main factors associated with anemia of chronic disease were the use of angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor antagonists (ARA-II) (OR=3.29; 95% CI, 1.36-7.94). The main factor associated with undefined anemia was initial heart failure (OR=5.41; 95% CI, 1.65-17.65). On the other hand, 8.1% of patients required transfusion, 6% were treated with erythropoietin and 25.3% were treated with iron. Both age (OR=1.04; 95% CI, 1-1.08) and hemoglobin level at admission (OR=1.81; 95% CI, 1.46-2.25) were associated with active treatment for anemia. CONCLUSIONS: A clinical study of anemia in patients with HF can establish an etiological diagnosis in 70% of cases, resulting in a more effective treatment.